The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients.
Ron Bentsur, CEO of Keryx, said: We believe that this single agent activity for perifosine once again demonstrates that perifosine is an active, novel agent with the potential to provide clinical benefit to patients with 2nd or 3rd line metastatic renal cell cancer. We look forward to evaluating future trial designs in patients with advanced renal cell carcinoma.